

REFERENCES FOR SUPPLEMENTARY MATERIALS

1. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7:80-93.
2. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013;159:130-137.
3. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods* 2012;3:80-97.
4. Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. *Liver Int* 2004;24:625-629.
5. Chai W, Zhao Q, Song H, Cheng C, Tian G, Jiang T. Treatment response and preliminary efficacy of hepatic tumour laser ablation under the guidance of percutaneous and endoscopic ultrasonography. *World J Surg Oncol* 2019;17:133.
6. Chang W, Lee JM, Lee DH, Yoon JH, Kim YJ, Yoon JH, et al. Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. *PLoS One* 2018;13:e0192173.
7. Chen K, Chen G, Wang H, Li H, Xiao J, Duan X, et al. Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. *J Hepatol* 2014;61:1304-1311.
8. Choi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, et al. Radiofrequency ablation using a separable clustered electrode for the treatment of hepatocellular carcinomas: A randomized controlled trial of a dual-switching monopolar mode versus a single-switching monopolar mode. *Korean J Radiol* 2021;22:179-188.
9. Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattani S, et al. Curative irradiation treatment of hepatocellular carcinoma: A multicenter phase 2 trial. *Int J Radiat Oncol Biol Phys* 2020;107:116-125.
10. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. *Liver Transpl* 2003;9:557-563.
11. Hirooka M, Hiraoka A, Ochi H, Koizumi Y, Michitaka K, Joko K, et al. Prospective cohort trial to confirm the efficacy of no-touch radio frequency ablation. *J Gastroenterol Hepatol* 2019;34:567-574.
12. Jiang FQ, Lu W, Yang C, Du P, Ma JP, Yang J, et al. Curative effect of transcatheter arterial chemoembolization combined with radiofrequency ablation in treating hepatic cell carcinoma and its effect on serum markers. *Cancer Biomark* 2017;20:17-22.
13. Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. *Cancer* 2017;123:3955-3965.
14. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. *Clin Cancer Res* 2006;12:543-548.
15. Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, et al. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. *Hepatol Res* 2021;51:461-471.
16. Lee P, Ma Y, Zacharias I, Bozorgzadeh A, Wilson S, Foley K, et al. Stereotactic body radiation therapy for hepatocellular carcinoma in patients with Child-Pugh B or C cirrhosis. *Adv Radiat Oncol* 2020;5:889-896.
17. Liao M, Zhong X, Zhang J, Liu Y, Zhu Z, Wu H, et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: A prospective randomized trial. *J Surg Oncol* 2017;115:971-979.
18. Lin JJ, Jin CN, Zheng ML, Ouyang XN, Zeng JX, Dai XH. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation. *Chin J Integr Med* 2005;11:104-110.
19. Liu R, Sun M, Shi L, Yu H. The efficacy assessment of radiofrequency ablation treatment on primary hepatocellular carcinoma by contrast enhanced ultrasonography. *Int J Clin Exp Med* 2016;9:16218-16223.
20. Ma CL, Sun RJ, Li J. Short-term effect of metronomic chemotherapy of low-dose Tegafur on patients with primary hepatic carcinoma after radiofrequency ablation. *Eur Rev Med Pharmacol Sci* 2018;22:3742-3748.

21. Müller C, Schöniger-Hekele M, Scherthaner R, Renner B, Peck-Radosavljevic M, Brichta A, et al. Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial. *Wien Klin Wochenschr* 2008;120:608-618.
22. Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D, et al. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. *J Hepatol* 2006;44:902-909.
23. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol* 2013;31:426-432.
24. Sheta E, El-Kalla F, El-Gharib M, Kobtan A, Elhendawy M, Abd-El salam S, et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. *Eur J Gastroenterol Hepatol* 2016;28:1198-1203.
25. Shibata T, Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. *Radiology* 2006;238:346-353.
26. Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. *Clin Cancer Res* 2018;24:73-83.
27. Wang-Yuan Z, Jiang-Zheng Z, Lu YD, Hao XB, Hong T, Huang F, et al. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. *Int J Hyperthermia* 2016;32:193-198.
28. Xu Z, Liu P, Zhang Y, Gao X. Clinical efficacy of accurate radiotherapy associated slow releasing cisplatin to the primary liver cancer. *Int J Clin Exp Med* 2016;9:5206-5212.
29. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2010;136:625-630.
30. Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. *Radiology* 2014;270:607-620.
31. Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. *Radiology* 2007;244:599-607.
32. Zheng ZJ, Fu J, Zhi F, Liu WJ, Guo YJ, Zhu DD, et al. The effects of interventional therapy on serum HTATIP2/TIP30, B7-H4 and short-term curative effect in primary hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 2018;22:6778-6783.